These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6476216)

  • 1. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells.
    Eckels KH; Scott RM; Bancroft WH; Brown J; Dubois DR; Summers PL; Russell PK; Halstead SB
    Am J Trop Med Hyg; 1984 Jul; 33(4):684-9. PubMed ID: 6476216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells.
    Halstead SB; Eckels KH; Putvatana R; Larsen LK; Marchette NJ
    Am J Trop Med Hyg; 1984 Jul; 33(4):679-83. PubMed ID: 6476215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. III. Reversion to virulence by passage of cloned virus in fetal rhesus lung cells.
    Halstead SB; Marchette NJ; Diwan AR; Palumbo NE; Putvatana R; Larsen LK
    Am J Trop Med Hyg; 1984 Jul; 33(4):672-8. PubMed ID: 6476214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans.
    Edelman R; Tacket CO; Wasserman SS; Vaughn DW; Eckels KH; Dubois DR; Summers PL; Hoke CH
    J Infect Dis; 1994 Dec; 170(6):1448-55. PubMed ID: 7995984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys.
    Eckels KH; Dubois DR; Putnak R; Vaughn DW; Innis BL; Henchal EA; Hoke CH
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):12-6. PubMed ID: 14740950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status.
    Scott RM; Eckels KH; Bancroft WH; Summers PL; McCown JM; Anderson JH; Russell PK
    J Infect Dis; 1983 Dec; 148(6):1055-60. PubMed ID: 6655288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. II. Attributes of virus cloned at different dog kidney passage levels.
    Halstead SB; Marchette NJ; Diwan AR; Palumbo NE; Putvatana R
    Am J Trop Med Hyg; 1984 Jul; 33(4):666-71. PubMed ID: 6476213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. I. Pre-clinical studies.
    Marchette NJ; Dubois DR; Larsen LK; Summers PL; Kraiselburd EG; Gubler DJ; Eckels KH
    Am J Trop Med Hyg; 1990 Aug; 43(2):212-8. PubMed ID: 1975159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys.
    Angsubhakorn S; Yoksan S; Bhamarapravati N; Moe JB; Marchette NJ; Pradermwong A; Sahaphong S
    Trans R Soc Trop Med Hyg; 1988; 82(5):746-9. PubMed ID: 3252595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans.
    Hoke CH; Malinoski FJ; Eckels KH; Scott RM; Dubois DR; Summers PL; Simms T; Burrous J; Hasty SE; Bancroft WH
    Am J Trop Med Hyg; 1990 Aug; 43(2):219-26. PubMed ID: 2389825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers.
    McKee KT; Bancroft WH; Eckels KH; Redfield RR; Summers PL; Russell PK
    Am J Trop Med Hyg; 1987 Mar; 36(2):435-42. PubMed ID: 3826504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers.
    Bancroft WH; Scott RM; Eckels KH; Hoke CH; Simms TE; Jesrani KD; Summers PL; Dubois DR; Tsoulos D; Russell PK
    J Infect Dis; 1984 Jun; 149(6):1005-10. PubMed ID: 6376649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. I. Attributes of uncloned virus at different passage levels.
    Halstead SB; Diwan AR; Marchette NJ; Palumbo NE; Srisukonth L
    Am J Trop Med Hyg; 1984 Jul; 33(4):654-65. PubMed ID: 6476212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
    Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
    J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of viraemia and limited antibody response of dengue virus immune rhesus monkeys after vaccination with DEN-2/S-1 vaccine.
    Kraiselburd E; Kessler MJ; Torres-Blasini G
    Trans R Soc Trop Med Hyg; 1984; 78(4):445-8. PubMed ID: 6548325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
    Durbin AP; Karron RA; Sun W; Vaughn DW; Reynolds MJ; Perreault JR; Thumar B; Men R; Lai CJ; Elkins WR; Chanock RM; Murphy BR; Whitehead SS
    Am J Trop Med Hyg; 2001 Nov; 65(5):405-13. PubMed ID: 11716091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques.
    Añez G; Men R; Eckels KH; Lai CJ
    J Virol; 2009 Oct; 83(20):10384-94. PubMed ID: 19656873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
    Edelman R; Wasserman SS; Bodison SA; Putnak RJ; Eckels KH; Tang D; Kanesa-Thasan N; Vaughn DW; Innis BL; Sun W
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):48-60. PubMed ID: 14740955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients.
    Bancroft WH; Top FH; Eckels KH; Anderson JH; McCown JM; Russell PK
    Infect Immun; 1981 Feb; 31(2):698-703. PubMed ID: 7216469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.